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Abstract Neurostimulation is now an established therapy for
the treatment of movement disorders, pain, and epilepsy.
While most neurostimulation systems available today provide
stimulation in an open-loop manner (i.e., therapy is delivered
according to preprogrammed settings and is unaffected by
changes in the patient’s clinical symptoms or in the underlying
disease), closed-loop neurostimulation systems, which modu-
late or adapt therapy in response to physiological changes,
may provide more effective and efficient therapy. At present,
few such systems exist owing to the complexities of designing
and implementing implantable closed-loop systems. This re-
view focuses on the clinical experience of four implantable
closed-loop neurostimulation systems: positional-adaptive
spinal cord stimulation for treatment of pain, responsive cor-
tical stimulation for treatment of epilepsy, closed-loop vagus
nerve stimulation for treatment of epilepsy, and concurrent
sensing and stimulation for treatment of Parkinson dis-
ease. The history that led to the development of the
closed-loop systems, the sensing, detection, and stimulation
technology that closes the loop, and the clinical experiences
are presented.
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Introduction
In the last 2 decades, since the US Food and Drug
Administration (FDA) approval of deep brain stimulation
(DBS) for the treatment of tremor in 1997 [1], neurostimulation
has become an important therapeutic option for patients with
diseases of the nervous system. Neurostimulation is now an
established therapy for treatment of essential tremor [2],
Parkinson disease (PD) [3, 4], epilepsy [5, 6], and neuropathic
pain [7, 8], and is being investigated for numerous other
neurologic and psychiatric disorders, including memory dis-
orders, depression, obsessive–compulsive disorder, and
Tourette syndrome [9, 10].
Most neurostimulation systems available today provide
stimulation in an open-loop manner, which means that stimu-
lation settings are preprogrammed and do not automatically
respond to changes in the patient’s clinical symptoms or in the
underlying disease. While open-loop stimulation paradigms
are effective, limitations of open-loop stimulation have be-
comemore evident as clinical experience grows. For example,
although open-loop spinal cord stimulation systems are gen-
erally effective for the treatment of pain, open-loop systems
may provide too much or too little therapy because the stim-
ulation settings are not automatically adjusted based on the
patient’s body position [11–13]. A closed-loop system may
provide improved and more consistent pain relief by automat-
ically adjusting the stimulation settings according to the pa-
tient’s body position. In another example, open-loop DBS
systems for the treatment of PD, while effective in managing
the motor symptoms, may be inefficient because the same
level of stimulation is provided regardless of the extent of
motor impairment [14]. A closed-loop system may provide
stimulation more efficiently by delivering stimulation only
when motor function is impaired.
Advancements in implantable technology have led to the
design and clinical introduction of implantable closed-loop
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neurostimulation systems that continuously sense physiolog-
ical signals, detect prespecified physiological changes, and
adjust therapy in response to the detected signals. Closed-
loop therapies may offer advantages relative to open-loop
therapies by increasing the efficacy of stimulation [14–16],
improving the clinical benefit of stimulation [16], and reduc-
ing the side effects of stimulation [14].
This review focuses on the clinical experience of implant-
able closed-loop neurostimulation systems for treatment of
pain, epilepsy, and movement disorders. The history that led
to the development of the closed-loop system, the sensing,
detection, and stimulation technology that closes the loop, and
the clinical experience are presented.
Pain
Background
Neurostimulation to treat pain was introduced clinically in
1967, when the first spinal cord stimulator was implanted to
stimulate the dorsal columns of the spinal cord [17]. Since
then, numerous technological developments, including im-
proved lead design and advanced programming capabilities,
have improved the efficacy of the therapy. Spinal cord stim-
ulation (SCS) is now a widely accepted form of therapy for
chronic intractable neuropathic pain and is the most common-
ly employed neurostimulation therapy for treatment of pain
[18].
SCS provides pain relief by interfering with pain signals
traveling along the spinal cord. To achieve optimum efficacy,
the stimulation settings must be adjusted for each patient.
Stimulation amplitude that is too low may be ineffective,
and stimulation amplitude that is too high may be perceived
as painful [11].
One of the challenges of SCS systems is to provide effec-
tive pain relief in all body positions. Because the stimulating
electrodes are typically situated in the epidural space, a change
in body position may change the epidural distance or the
longitudinal distance, which may result in a change in the
location and intensity of the stimulation-induced effect
[11–13, 19]. For example, the same stimulation settings that
are effective when the patient is standing may be too intense
when the patient is lying down.
Open-loop SCS systems address this issue using a patient-
controlled programmer that allows the patient to adjust the
stimulation intensity within clinician-prescribed limits.
However, the patient may need to make multiple adjustments
during the day to maintain adequate pain control. Recently, a
closed-loop SCS system, the RestoreSensor system
(Medtronic, Minneapolis, MN, USA), has been approved by
the US FDA to provide automatic adjustments in stimulation
according to the patient’s body position (Fig. 1).
Closed-loop Technology
The RestoreSensor system uses a 3-axis accelerometer that
senses the patient’s body position and activity, and then ad-
justs the stimulation settings according to the body position. In
order to provide this closed-loop therapy, the RestoreSensor
neurostimulator must first be trained to recognize different
body positions. During this process, the patient is positioned
in multiple orientations such as upright, lying prone, lying
supine, lying on the left side, and lying on the right side. Data
from the 3-axis accelerometer are linked to each of these
positions, and patient-specific stimulation settings are opti-
mized for each position.
Once the position-adaptive stimulation feature is pro-
grammed, the system detects changes in body position and
activity in real time and automatically adjusts stimulation
according to the preprogrammed settings.
Clinical Experience
Two clinical studies assessed safety and efficacy of closed-
loop SCS for pain [16, 20].
The first evaluated the feasibility and utility of an
accelerometer-based algorithm to automatically adjust
stimulation settings based on body position or activity
[20]. This prospective, open-label, randomized study
enrolled 20 patients across 2 centers. Fifteen participants
completed the in-clinic protocol to provide data for the
study.
Prior to entering this study, patients had already been
implanted with either the Restore or RestoreAdvanced spinal
cord stimulator (Medtronic) for at least 3 months, demonstrat-
ed stable pain control with their neurostimulation system, and
used their patient programmer to change the stimulation
Fig. 1 The Medtronic RestoreSensor SureScan MRI SCS device
(Medtronic, Minneapolis, MN, USA). Reprinted with the permission of
Medtronic, Inc. © 2013
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amplitude in response to body position or activity at least
twice a day during a 3-day baseline period.
During the in-clinic phase, the patient’s baseline stimula-
tion settings were recorded. Additionally, stimulation thresh-
olds were obtained for 8 different positions: standing, sitting,
lying supine, lying on right side, lying prone, lying on left
side, reclining at 45°, and walking on a treadmill. An external
sensor containing a triaxial accelerometer was then fitted to
the patient, and accelerometer measurements were taken for a
subset of those positions. The external sensor communicated
directly with a programmer to adjust the stimulation settings
according to the measured body position.
Each patient self-rated their overall satisfaction for each of
the 8 positions when stimulation was adjusted manually and
with two different automatic stimulation adjustment modes.
Patients reported significantly higher satisfaction using the
automatic stimulation adjustment modes compared with the
manual adjustment mode, and 74 % of patients reported that
stimulation settings using the automatic adjustment algorithm
were “just right” (vs “too high” or “too low”). This study
demonstrated the feasibility and utility of using a triaxial
accelerometer to measure the body position in order to auto-
matically adjust the stimulation settings.
The automatic adjustment algorithm was subsequently
evaluated in a clinical study of an implantable spinal cord
neurostimulation system [16]. A prospective, multicenter,
open-label, randomized crossover study was conducted in 79
patients implanted with the RestoreSensor (Medtronic) SCS
system to assess whether the position-adaptive stimulation
feature provided benefit in terms of pain relief and/or conve-
nience compared with not using the feature.
For the first 4 weeks after implantation of the system, only
manual adjustment of stimulation was enabled. Patients were
then randomized 1:1 to receive either position-adaptive stim-
ulation or conventional manual programming for 6 weeks, and
were then crossed over to receive the other type of stimulation
for 6 weeks.
In the intent-to-treat analysis, 86.5 % of patients achieved
the primary objective of improved pain relief with no loss of
convenience, or had improved convenience with no loss of
pain relief using automatic position-adaptive stimulation com-
pared with using conventional manual programming adjust-
ment alone. Moreover, patients reported improved comfort
during position changes (80.3 %), improved activity
(69.0 %), and improved sleep (47.9 %) with position-
adaptive stimulation. There were 25 adverse events (AEs)
related to undesirable changes in stimulation; however, only
9 of the events occurred during the position-adaptive stimula-
tion arm of the study [16].
These studies illustrate how a fairly straightforward and
simple closed-loop system using body orientation as a feed-
back signal significantly improved the patient experience.
Closed-loop position-adaptive stimulation improved patient-
reported pain relief, activity, sleep, and convenience compared
with using manual programming adjustment alone. Future
SCS systems may employ more sophisticated closed-loop
algorithms, such as using electrically evoked compound ac-
tion potentials to automatically adjust stimulation parameters,
which could allow for even more effective and efficient pain
control [21].
Epilepsy
The earliest report of applying electrical stimulation to the
brain to treat seizures in humans is by Penfield and Jasper in
1954 [22]. In their acute experiments, they observed that in
some cases electrical stimulation of the cortex resulted in a
flattening of the local electrocorticogram (both normal
rhythms and spontaneous epileptiform discharges).
Numerous studies published over the last 6 decades have
evaluated the safety and efficacy of brain stimulation to treat
epilepsy [23]. Promising results were reported for stimulation
of the cerebellum [24–26], caudate nucleus [27–29],
centromedian nucleus [28, 30, 31], subthalamic nucleus
(STN) [32], hippocampus [33–35], and the anterior nucleus
of the thalamus [36–38]. However, with the exception of a
randomized double-blinded controlled trial of stimulation of
the anterior nucleus of the thalamus as adjunctive treatment of
medically intractable partial onset seizures in adults [38], these
studies were largely uncontrolled, small, and have not been
replicated.
There are currently 2 neurostimulation therapies approved
by the US FDA for treatment of epilepsy: open-loop vagus
nerve stimulation (VNS Therapy Cyberonics, Houston, TX,
USA) and closed-loop responsive cortical stimulation (RNS
System, NeuroPace, Mountain View, CA, USA).
The following two sections describe the background, the
closed-loop technology, and clinical experience of the US
FDA-approved closed-loop responsive cortical stimulation
system and an investigational closed-loop vagus nerve stimu-
lation system, which builds on the approved open-loop vagus
nerve stimulation technology.
Closed-loop Responsive Cortical Stimulation
Background
Initial experiments assessed the safety and efficacy of respon-
sive electrical stimulation for epilepsy during in-patient intra-
cranial monitoring to determine whether the patient was a
candidate for epilepsy surgery. A routine procedure during
this evaluation is to deliver focal cortical stimulation to iden-
tify functional and epileptogenic regions. At times, the elec-
trical stimulation elicits afterdischarges (ADs), which are
rhythmic discharges that are similar to spontaneous
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epileptiform activity. Lesser et al. [39] observed that a brief
burst of electrical stimulation (similar to the stimulation used
to elicit ADs) could also terminate an AD. The most effective
stimulation to terminate ADs was brief (0.5–1 s), ap-
plied early (within 4.5 s of the AD), and applied at the site of
the AD [39, 40].
This work paved the way for the development of closed-
loop responsive stimulation systems designed to deliver elec-
trical stimulation in response to spontaneous epileptiform
activity. The first such systems were large, nonimplantable
systems, developed as proof-of-concept prototypes to assess
whether closed-loop responsive stimulation was feasible and
could be effective [41, 42].
Peters et al. [41] used an external bedside system that
performed real-time seizure detection and automatically de-
livered electrical stimulation in response to the seizure detec-
tion. This system was evaluated in 8 patients undergoing
intracranial monitoring [43]. Four patients received respon-
sive stimulation directly to the epileptogenic zone (local
closed-loop) and 4 received responsive stimulation to the
anterior thalami (remote closed-loop). The mean reduction in
seizures in the local closed-loop stimulation group was 55.5%
and 40.8 % in the remote closed-loop group. Four of the 8
patients had a≥50 % reduction in seizures with responsive
stimulation (3 with local closed-loop stimulation and 1 with
remote closed-loop stimulation). Kossoff et al. [42] also re-
ported on the experience using an external responsive
neurostimulator in 4 patients. Stimulation delivered in re-
sponse to epileptiform activity appeared to reduce the number
of clinical seizures and to suppress electrographic seizures.
These studies demonstrated that closed-loop responsive stim-
ulation was feasible and provided preliminary evidence that
responsive stimulation could reduce seizures.
Closed-loop Technology
The RNS System is a responsive cortical neurostimulator
system approved by the US FDA as an adjunctive therapy in
reducing the frequency of seizures in individuals aged 18 years
or older with partial onset seizures who have undergone
diagnostic testing that localized no more than 2 epileptogenic
foci, are refractory to≥2 antiepileptic medications, and cur-
rently have frequent and disabling seizures (motor partial
seizures, complex partial seizures, and/or secondarily gener-
alized seizures). The RNS System includes a neurostimulator
that is implanted in the cranium and connected to 1 or 2
recording and stimulating depth and/or cortical strip leads that
are surgically placed in the brain at the seizure foci (Fig. 2).
The closed-loop neurostimulator provides responsive electri-
cal stimulation directly to 1 or 2 seizure foci when abnormal
electrocorticographic activity is detected. The system includes
a programmer for the physician, a remote monitor for the
patient, and a secure internet-accessed database for storage
of neurostimulator data obtained by the programmer or remote
monitor.
Sensing and Data Storage
The neurostimulator continuously senses and monitors
electrographic activity through the implanted cortical depth
and strip leads. The neurostimulator records the date and time
of all detections and stimulations, and stores segments of the
electrographic data for review by the physician. Electrographic
data storage is triggered by detection, responsive stimulation,
scheduled time of the day, magnet (used by the patient to
indicate a seizure), and/or other events as programmed by the
physician. These data allow physicians to assess detection
sensitivity and effects of stimulation.
Detection
The detection algorithms in the neurostimulator are computa-
tionally efficient and optimized in order to perform real-time
detection within the constraints of currently available
implantable technology, such as limited power and pro-
cessing capabilities [44]. Three detection tools (bandpass,
line-length, and area) are provided. The detection parameters
are highly configurable and are selected by the physi-
cian to adjust the sensitivity, specificity, and latency of
the detection.
The bandpass tool is similar to that described by Gotman
[45], and is used to detect spikes and rhythmic activity occur-
ring in specific frequency ranges. This tool uses “half-waves”,
which are segments of the electrographic signal partitioned at
local minima and maxima. The amplitude and duration of the
half-waves are representative of the amplitude and frequency
components of the electrographic signal.
The line-length algorithm, described byD’Alessandro et al.
[46] and Esteller et al. [47] identifies changes in both
Fig. 2 The RNS Neurostimulator connected to the NeuroPace
Depth Lead and NeuroPace Cortical Strip Lead (NeuroPace, Mountain
View, CA, USA)
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amplitude and frequency. The line-length is defined as the
average of absolute sample-to-sample amplitude differences
within a window. A short-term sliding window average
(128 ms–4 s) is compared with a long-term sliding window
average (4 s–16 min). Detection occurs when the short-term
measurement crosses an absolute or relative threshold derived
from the long-term measurement.
The area feature is similar to an energy or power
measurement and identifies changes in overall signal
energy without regard for frequency [48–50]. Area is
defined as the average absolute area-under-the-curve of
the electrographic signal. As with line-length, a short-term
window average is compared with a long-term background
window average, and detection occurs when a previously
defined threshold is crossed.
These 3 detection algorithms are efficient (requiring low
computational power), and can be configured to detect
electrographic events within a fraction of a second or to detect
more subtle changes in amplitude, frequency, and/or power
that occur over several seconds.
Stimulation
The neurostimulator delivers current-controlled, charge-
balanced biphasic pulses, and is programmed by the
physician to deliver stimulation frequencies ranging
from 1 to 333 Hz, current amplitudes from 0.5 to 12.0 mA,
and pulse-widths from 40 to 1000 μs. The stimulation
montage can be configured to deliver current between
any combination of electrodes, including the neurostimulator
case.
Clinical Use
The RNS System is not a seizure predictor and cannot deter-
mine if the patient has a clinical seizure. In the clinical expe-
rience to date, the neurostimulator has typically been pro-
grammed to detect spike and slow waves, rhythmic changes
in frequency, or changes in amplitude typical of the
electrocorticographic features that sometimes progressed to
an electrographic and/or clinical seizure. The most common
stimulation programming was an amplitude of 1.5–3.0 mA, a
pulse width of 160 μs, a stimulation burst duration of 100–
200 ms, and a pulse frequency of between 100 and 200 Hz.
The majority of patients received stimulation in response to
detections 600–2000 times a day for a cumulative total of<5
mins of stimulation over 24 h. As this closed-loop stimulation
was in response to detections of specific electrocorticographic
patterns, and it was not possible to know which of these
detections would have progressed to an electrographic (or
clinical) seizure, the concept of false-positive or false-
negative seizure detections was therefore not relevant to this
stimulation approach.
Clinical Experience
Safety and efficacy of the RNS System as an adjunctive
treatment in adults with medically intractable partial-onset
seizures was established in 3 clinical trials: a 2-year primarily
open-label safety study (feasibility study, n=65), a 2-year
double-blinded randomized sham-stimulation controlled
study (pivotal study, n=191), and a long-term extension study
(long-term treatment study) designed to collect an additional
7 years of efficacy and safety data in patients completing the
feasibility or pivotal studies.
The pivotal study was a multicenter, double-blinded, ran-
domized sham-stimulation controlled study to demonstrate
the safety and effectiveness of the RNS System as an adjunc-
tive treatment for adults with medically intractable partial-
onset seizures arising from 1 or 2 seizure foci. Patients were,
on average, 34.9 years old and had epilepsy for 20.5 years.
Nearly one-third (32 %) had prior therapeutic epilepsy surgery
(resection, subpial transection, and/or callosotomy), and more
than a third (34 %) had previously been treated with a vagus
nerve stimulator.
The effectiveness of responsive stimulation was assessed
by comparing the seizure reduction in the group receiving
active stimulation (treatment group) versus the group receiv-
ing no stimulation (sham group) during a 12-week blinded
period relative to a preimplant baseline. The primary effec-
tiveness endpoint was met: the reduction in seizure frequency
in the treatment group (–37.9%)was significantly greater than
that in the Sham group (–17.3 %; p=0.012) [6]. There was no
difference in effectiveness in patients with mesial temporal
lobe seizure onsets compared with patients with neocortical
seizure onsets, in patients whose seizures arose from 1 com-
pared with 2 foci, in patients who had been treated with vagus
nerve stimulation (VNS) compared with those who had not,
and in patients who had already undergone a therapeutic
epilepsy surgery compared with those who had not.
During the open-label period of the study, when all patients
had the opportunity to receive responsive stimulation, seizure
reduction continued to improve. The median percent reduc-
tion in seizures was 44 % at 1 year and 53 % at 2 years
postimplant compared with baseline [51].
Safety was assessed using AE data. The RNS System
serious AE rate was no worse than the literature-derived
serious AE rate for comparable procedures. Stimulation was
well tolerated. There was no difference in the frequency or
type of AE between the treatment and sham groups, except for
side effects of antiepileptic medications, which were more
common in the sham group (5 patients, all mild events) than
the treatment group (none). (Refer to the RNS System product
labeling for detailed disclosure of specific indications, contra-
indications, warnings, precautions, and AEs.)
Additional assessments included a quality of life inventory,
neuropsychological evaluations, and mood inventories. At 1
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and 2 years after implantation, patients reported significant
improvements in overall quality of life (p<0.001) and in 9 of
the primary scale scores, including memory, concentration,
and language [51]. There was no significant deterioration in
any neuropsychological measures or any of the mood inven-
tories at the end of the blinded period compared with the
baseline period, or at 1 and 2 years postimplant, indicating
there were no acute, delayed, or longer-term adverse
effects of responsive stimulation on neuropsychological func-
tion and mood.
These results demonstrate that closed-loop responsive
stimulation to the seizure focus can reduce the frequency of
partial onset seizures, is well-tolerated, and is acceptably safe.
Closed-loop VNS
Background
Open-loop VNS is approved by the US FDA for use as an
adjunctive therapy in reducing seizure frequency in adults and
adolescents over the age of 12 years with partial-onset seizures
that are refractory to antiepileptic drugs. Intermittent sched-
uled stimulation is delivered to the vagus nerve. A typical
stimulation schedule is 30 s “on” and 5 min “off,” but this can
be adjusted by the physician. By moving a magnet over the
VNS pulse generator, patients may also initiate on-demand
stimulation bursts to provide additional VNS therapy during
an aura or at the onset of a seizure.
Two randomized, blinded, active-control (high-stimula-
tion/low-stimulation) trials evaluated the safety and efficacy
of open-loop VNS therapy [5, 52]. The median percent reduc-
tion in daily seizures was 23–24 % in the high stimulation
group and 6–21% in the low stimulation group. The reduction
in seizures in an open-label extension study was 31% at 1 year
and 41 % at 2 years. (Refer to the VNS therapy product
labeling for detailed disclosure of specific indications, contra-
indications, warnings, precautions, and AEs.)
The concept of closed-loop VNS therapy emerged from the
experience with magnet-activated stimulation, where a mag-
net is used by the patient or caregiver to trigger additional
bursts of stimulation at the time of an aura or seizure onset.
One prospective and 1 retrospective study evaluated magnet-
activated VNS therapy [53, 54]. The first was a single-center,
prospective study of 35 patients that was designed to assess
the efficacy of magnet-activated stimulation [53]. After im-
plantation of the VNS system, patients and their caregivers
were provided with a magnet and instructed how to use the
magnet to provide additional stimulation when an aura or
seizure onset occurred. Of the 35 implanted patients, 21 (or
their caregivers) were able to use the magnet and provide
reliable seizure information. Fourteen of the 35 patients were
unable to use the magnet: 9 because they had no auras or their
seizures were too brief; 3 had become seizure-free before the
magnet was provided; and 2 had unreliable data. Of the 21
patients who were able to use the magnet, 14 reported a
positive effect of the magnet and 7 reported no effect of the
magnet. Of note, only 3 patients were able to use the magnet
themselves. In most cases, support from caregivers was nec-
essary. Data from this study suggest that acute VNS delivered
at the onset of a seizure may provide added benefit to the
standard scheduled VNS, but reliable manual delivery of
stimulation may be difficult to achieve.
A second, retrospective study evaluated magnet usage
during two open-loop VNS trials: the E03 and E04 trials
[54]. In the randomized, double-blind, controlled, E03 trial,
patients were randomized 1:1 to receive therapeutic VNS
therapy (treatment group) or nontherapeutic stimulation (ac-
tive control group). During the blinded period of the trial,
magnet-activated stimulation was on for the treatment group
and off for the active control group. Of the 114 participants in
the E03 study, 92 (or their caregivers) used the magnet (50 in
the treatment group and 42 in the active control group). The
treatment group reported that 21.3 % of the seizures that
received magnet-activated stimulation were terminated com-
pared with 11.9 % in the active-control group (p=0.08).
Additionally, the treatment group was more likely to report
improvement with magnet usage compared with the active
control group (p=0.05).
During the open-label E04 trial, 86/124 participants used
their magnets. Of the 86 patients (or caregivers) who used the
magnets, 22 % reported seizure termination, 31 % reported
seizure diminution, and 47 % reported no effect of magnet-
activated VNS therapy. Patient-reported outcomes were avail-
able for 9482 seizures for which magnet-activated VNS was
used: for 2211 seizures (24 %) magnet-activated VNS termi-
nated the event, for 3638 seizures (38 %) magnet-activated
VNS diminished the event, and for 3633 seizures (38 %)
magnet-activated VNS did not affect the event.
Results from both studies of magnet-activated stimulation
suggest that there could be a positive effect of additional VNS
therapy during an aura or at the onset of a seizure. However,
both studies also revealed that most patients were unlikely to
be able to use the magnet on their own—a caregiver was
typically involved in activating the additional stimulation.
This led to the development of a closed-loop VNS system,
the AspireSR (Cyberonics), which is an investigational vagus
nerve stimulator that automates the delivery of additional
stimulation using a cardiac-based seizure detector.
Closed-loop Technology
Cardiac-based seizure detection relies on changes in the heart
rate at the onset or during a seizure. The most frequently
reported type of seizure-related cardiac change is ictal tachy-
cardia, or an increase in heart rate with seizure, which occurs
in>70 % of seizures [55–58]. Thus, several groups have
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proposed cardiac-based seizure detection based on this in-
crease in heart rate [59–62].
Although the cardiac-based seizure detection algorithm for
the AspireSR generator has not been published, one compu-
tationally efficient approach that could be performed in real-
time in an implantable system is to track the heart rate using
both long- and short-term trends [59]. The long-term heart rate
trend represents the background rate, which may change
slowly over time based on the patient’s activity level. The
short-term heart rate trend represents the foreground rate.
When the foreground heart rate exceeds a threshold relative
to the background heart rate, an event is detected. Because the
threshold is based on the background heart rate, it automati-
cally adjusts to the patient’s underlying activity.
Clinical Experience
The AspireSR is a vagus nerve stimulator with a cardiac-based
seizure detection feature. The performance of the cardiac-
based seizure detection feature was evaluated in a study of
31 patients. Patients implanted with the AspireSR generator
were observed in epilepsy monitoring units for up to 5 days to
identify seizures and collect heart rate data. More than 80% of
seizures that were accompanied by ictal tachycardia were
detected by the AspireSR generator. Thus, the primary end-
point of the study was met. The potential false detection rates
were low. The detections occurred close, and in some cases
prior, to seizure onset. This study demonstrated that the
cardiac-based seizure detection algorithm implemented in




DBS has been a treatment option for movement disorders
since 1997 when the first DBS system was approved for
treatment of tremor [1]. Over the last 2 decades, open-loop
DBS has proven to be a valuable and effective therapy option
for patients with PD, essential tremor, or dystonia whose
motor symptoms cannot be controlled by drug therapy alone
[3, 4, 64–67].
Despite the success of open-loop DBS for movement dis-
orders, many believe that closed-loop technology can improve
the therapy by potentially reducing the side effects of stimu-
lation and/or improving the efficacy of stimulation. For ex-
ample, side effects associatedwithDBS such as impairment of
speech, gait, and balance may be ameliorated by a closed-loop
responsive stimulation approach where stimulation is deliv-
ered intermittently [14, 68, 69]. Additionally, closed-loop
responsive or adaptive stimulation may improve the efficacy
of DBS [14, 15]. Indeed, Rosin et al. [15] discovered that
delivering closed-loop stimulation to the internal segment of
the globus pallidus in response to action potentials recorded in
the primary motor cortex is more efficient and effective in
alleviating Parkinsonian motor symptoms than continuous
stimulation.
There are also other potential advantages of closed-loop
stimulation. Closed-loop responsive stimulation may increase
the battery longevity, thus exposing the patient to fewer
neurostimulator replacement procedures. Additionally,
closed-loop systems may facilitate the process of identifying
the optimal stimulation settings by using a physiological
signal as a biomarker to titrate the stimulation parameters,
rather than relying on clinically overt symptoms [70, 71].
Thus, there is significant interest in developing closed-loop
DBS systems for treatment of movement disorders.
A number of approaches have been proposed using various
physiological signals for feedback in the closed-loop system,
including electromyography [72–74] and single- or multi-unit
recordings [15]. However, these signals are not amenable to
chronic recording. Perhaps the most practical approach is to
leverage existing open-loop neurostimulation systems and use
local field potentials (LFPs) sensed from the stimulating elec-
trode to close the loop [14, 75].
For treatment of PD, several groups have proposed using the
power in the beta frequency band (13–30 Hz) of the LFP in the
STN as a biomarker for closed-loop stimulation [76–78]. In
patients with PD, there is often a prominence in the beta
frequency band that is correlated with the severity of motor
symptoms and is suppressed with levodopa treatment [79], as
well as with DBS [76, 79, 80].Moreover, the suppression of the
beta activity is correlated with improved motor performance
[76]. Therefore, the beta bandmay be a useful biomarker for the
severity of motor symptoms and the efficacy of stimulation.
Little et al. [14] provided a proof-of-principle of this ap-
proach. In 8 patients undergoing DBS implantation for PD,
the LFP recorded from the stimulating electrode implanted in
the STN was used to trigger closed-loop stimulation.
Specifically, the LFP was filtered and rectified to produce an
“online” value of beta amplitude. This signal was used to
trigger stimulation via a user-defined threshold such that stim-
ulation was delivered approximately 50 % of the time.
Stimulation, once triggered, was sustained until the beta am-
plitude fell below the threshold. The authors reported that this
closed-loop stimulation resulted in improved motor response
relative to continuous open-loop stimulation. This research
demonstrates that the LFP in the STN could be a useful
biomarker to control DBS.
Closed-loop Technology
A fully implantable closed-loop DBS system has recently
been developed for investigational use. This system, the
Activa PC+S neurostimulator (Medtronic), is based on the
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Activa PC neurostimulator with additional sensing, stimula-
tion, and detection features (Fig. 3).
The main technical challenge in designing a closed-loop
concurrent sensing and stimulation system, in which sensing
is performed through the same leads as stimulation, is in sepa-
rating the stimulation signal (artifact) from the signal of interest.
Stanslaski et al. [81, 82] describe a systems-level approach to
minimizing the stimulation interference. This approach in-
cludes design elements in the sensing component, the stimula-
tion component, and the detection algorithm component.
Sensing
Three key design elements in the sensing component contrib-
ute to the elimination of the stimulation artifact. First, by using
differential sensing and electrodes that are symmetric in ge-
ometry about the stimulating electrode, a large component of
the stimulation artifact can be rejected as a common mode
disturbance. Second, a front-end filter can be configured to
suppress the high frequency associated with stimulation. For
example, a stimulation frequency of 140 Hz can be suppressed
with a 100-Hz low-pass filter. Third, a spectral bandpower
processor can be used to isolate the signal power in the
specific frequency band of interest, thus separating the neural
biomarkers from the stimulation harmonics.
Stimulation
While the design elements in the sensing component are key
to suppressing the stimulation artifact in the frequency band of
interest, careful selection of the sampling rate and the
stimulation frequency are also necessary to separate the stim-
ulation artifact from the signal of interest. Although the stim-
ulation frequency may be higher than the frequency band of
interest, the stimulation frequency and its harmonics may be
aliased back into lower frequency bands depending on the
sampling rate. Therefore, the design includes numerical anal-
ysis methods to identify stimulation frequencies that minimize
the interference with the band of interest based on the sam-
pling rate.
Detection Algorithm
Finally, the design includes detection algorithms that further
distinguish the information in the signal of interest from the
stimulation signal. For example, supplementing the physio-
logical spectral channels with independent information about
the stimulation energy may allow a classification algorithm
such as a support vector machine to better separate the stim-
ulation signal from the signal of interest.
These design elements, as described by the authors
“with modest performance in each individual block but
acceptable overall performance” enable measurement of the
LFP in the STN during stimulation, thus paving the way for
closed-loop DBS.
Proof-of-concept of the concurrent sensing and stim-
ulation design was demonstrated in a large animal
(ovine) model with leads implanted in the thalamus
and hippocampus [71, 81]. Evoked potentials and LFPs
could be recorded during stimulation. Moreover, the evoked
potentials were stable for>1 year, demonstrating the utility of
the system as a chronic implant [71].
Clinical Experience
The investigational Activa PC+S DBS is currently being used
in a clinical trial to study changes in neuronal oscillations
during tremor, repetitive movement, and freezing episodes
relative to rest in patients with PD, with the first human
implants in 2013 [83]. There have been no published reports
on experience with the system.
Discussion
We have reviewed 4 implantable closed-loop neurostimulation
systems: positional-adaptive SCS for treatment of pain, respon-
sive cortical stimulation for the treatment of epilepsy, closed-
loop VNS for the treatment of epilepsy, and concurrent sensing
and stimulation for the treatment of PD. At present, few such
systems exist owing to the complexities of designing and
implementing such a system. The technical challenges include
incorporating physiological sensors that add minimal risk to the
patient, and developing algorithms that detect in real-time and
Fig. 3 The Activa® PC+S deep brain neurostimulator (Medtronic, Min-
neapolis, MN, USA). Reprinted with the permission of Medtronic, Inc. ©
2013
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require low computational power. The scientific and clinical
challenges include determining the physiological markers for
specific symptoms, the anatomical target in which to sense and
stimulate, the physiological changes to detect, and how to
deliver andmodulate the stimulation in response to the detected
event and, ultimately, the clinical symptoms. However, the
clinical experience from these systems support the notion that
closed-loop therapy can be more effective than open-loop ones,
and therefore underscores the importance of continued effort in
developing closed-loop systems and in identifying promising
clinical applications. Future applications of closed-loop
neurostimulation may include treatment of major depression
[84], Tourrette syndrome [85], and other neuropsychiatric dis-
orders. The success of closed-loop SCS for the treatment of
pain and closed-loop responsive cortical stimulation for treat-
ment of epilepsy pave the way for development of these other
closed-loop neurostimulation systems.
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